To identify efficacy and safety of Telmisartan/Rosuvastatin co-administration in hyperlipidemia control in hypertensive patients with hyperlipidemia compared to each monotherapy.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
310
The Catholic University of Saint Mary's Hosiptal
Seoul, South Korea
RECRUITING•Change in seated diastolicblood pressure at 8 weeks compared to the base value
Time frame: at the 8 weeks
Change in LDL-Cat 8 weeks compared to the base value (% change)
Time frame: at the 8 weeks
Change in seateddiastolic blood pressure
Time frame: at 2,4 8 weeks
Change in seated systolic blood pressure
Time frame: at 2,4,8weeks
Rate of patients achieving a therapeutic purpose according to JNC VII Guideline [therapeutic purpose for blood pressure: < 140/90 mmHg (however, < 130/80 mmHg for Group III)]
Time frame: at 2, 4 and 8 weeks
Change in LDL-Cat compared to the base value (% change)
Time frame: 2, 4 and 8 weeks
Change in TC, TG, HDL-C and Apolipoprotein B compared to the base value (% change)
Time frame: at 2, 4 and 8 weeks
Rate of patients achieving a therapeutic purpose according to NCEP ATP III Guideline therapeutic purpose for LDL-C- (Group I: < 160 mg/dL, Group II: < 130 mg/dL, Group III: < 100 mg/dL)
Time frame: at 2, 4 and 8 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.